

Date: 1st April, 2026

BSE Limited

P. J. Towers, Dalal Street, Fort,
Complex, Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla
Bandra (East), Mumbai - 400 051
NSE Symbol: PPLPHARMA

**Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015
(‘SEBI Listing Regulations’) – Completion of acquisition of Kenalog®, a
branded commercial injectable product**

Dear Sir / Madam,

With reference to Company’s earlier intimation dated 28th January, 2026, we hereby inform that Piramal Critical Care B.V., step-down wholly owned subsidiary of Piramal Pharma Limited (‘the Company’), has successfully completed the acquisition of Kenalog® and its associated brands from Bristol-Myers Squibb Company (‘BMS’).

With the completion of the Kenalog® acquisition, the Company strengthens its Complex Hospital Generics portfolio and reinforces its presence across key markets including the United States, Europe, and Asia Pacific.

Thank you.

Yours truly,

For Piramal Pharma Limited

Pratibha Mishra
Interim Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com